Key result
The Roche 3rd-generation cTnT assay showed excellent agreement with the 2nd-generation assay, with concordance up to 0.2 microg/l.
Why the study?
Does the recalibrated Roche 3rd-generation cTnT assay agree with the 2nd-generation assay in patients admitted to the coronary care unit?
Observational (n=77)
Does the recalibrated Roche 3rd-generation cTnT assay agree with the 2nd-generation assay in patients admitted to the coronary care unit?
The recalibration of the Roche 3rd-generation cTnT assay does not affect clinical decision limits up to 0.2 microg/l, ensuring consistency with the 2nd-generation assay for detecting increased cardiac risk.
Answers are grounded in this paper and cite their sources.
Supports consistent troponin thresholds with the recalibrated assay in CCU patients; leaves open prospective outcome validation in broader cohorts.
OBJECTIVE: To assess the effect of recalibration of the Roche 3rd-generation cTnT assay with recombinant human cardiac troponin T (cTnT) standards on clinical decision limits. MATERIALS AND METHODS: Serum samples from 77 patients (66 +/- 16 years) admitted to the coronary care unit were assayed using the 2nd- and 3rd-generation cTnT assays. RESULTS: There was excellent agreement (r = 0.99 Spearman, 95% CI 0.99-1.0; p <or= 0.0001, n = 153) between the 2nd- and 3rd-generation cTnT assays across the analytical range, but there was a curvilinear relationship between values. There was concordance between the 2nd- and 3rd-generation cTnT values in the range from 0 to 0.2 microg/l. Above 0.2 microg/l, however, there were increasing but predictable differences. CONCLUSION: There was no statistical difference between the 2nd- and 3rd-generation cTnT assays, demonstrated by a linear relationship below 0.2 microg/l. This confirms that the 3rd-generation assay was calibrated to that of the 2nd-generation assay in the range of 0-0.2 microg/l. The detection limit and upper reference limit of normal will be unaffected by this change in calibration. A non-linear relationship at higher 2nd-generation concentrations (0.2-25.0 microg/l) was observed. Clinical decision limits up to 0.2 microg/l, associated with increased cardiac risk, are unaffected by the assay calibration, but values greater than 0.2 microg/l are affected.
No takes yet. Share an insight, caveat, or question.
Gaze et al. (2005) conducted an observational in Admitted to the coronary care unit (n=77). Roche 3rd-generation cTnT assay vs. Roche 2nd-generation cTnT assay was evaluated on Agreement between 2nd- and 3rd-generation cTnT assays (r = 0.99, 95% CI 0.99-1.0, p=<=0.0001). The Roche 3rd-generation cTnT assay showed excellent agreement with the 2nd-generation assay, with concordance up to 0.2 microg/l.
Synapse has enriched 10 related papers. Consider them for comparative context: